TheGlobal Focal Segmental Glomerulosclerosis Clinical Trial Pipeline Highlights, 2019 - Analysis on Clinical Trial Stages, Drug Mechanism Classes, Short-term Launch Highlights, and Companies ...

The Focal segmental glomerulosclerosis (FSGS) market report gives a thorough understanding of FSGS symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and ...

Find all the latest on focal segmental glomerulosclerosis at Medical Xpress. Your go-to source for news, research, and medical breakthroughs.

Retrophin announces publication of phase 2 DUET study of sparsentant for the treatment of focal segmental glomerulosclerosis in the Journal of the American Society of Nephrology. News release.

Focal and segmental glomerulosclerosis (FSGS) is the most common histologic pattern of renal injury seen in adults with idiopathic proteinuria.

Focal segmental glomerulosclerosis-attributed kidney failure may be linked with significant clinical and economic burdens, according to a recently published study.“The prevalence and incidence ...

Dr Szczech comments on a novel study that provides another piece of the puzzle in a common glomerular disease.

Treatment of focal segmental glomerulosclerosis with adrenocorticotropic hormone gel may be a viable alternative for patients who fail to respond to therapeutic plasma exchange and rituximab after ...

Kidney involvement can be a serious complication of hematopoietic stem cell transplantation. In this Case Study, Fofi and colleagues describe a rare case of focal segmental glomerulosclerosis ...

Focal segmental glomerulosclerosis is a leading cause of kidney failure worldwide, yet approved treatments for this condition are lacking. New research findings comparing sparsentan with ...

Focal segmental glomerulosclerosis (FSGS) is a kidney disease that leads to renal failure, and it affects individuals from different ancestries, the highest prevalence being among African and African ...